🚀 VC round data is live in beta, check it out!
Vaxcyte Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vaxcyte and similar public comparables like Huadong Medicine, Haisco Pharmaceutical, Krka, Eisai Co. and more.
Vaxcyte Overview
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Founded
2013
HQ
Employees
507
Website
Sectors
Financials (LTM)
EV
$8B
Vaxcyte Financials
Vaxcyte reported last 12-month revenue of — and negative EBITDA of ($977M).
In the same LTM period, Vaxcyte generated — in gross profit, ($977M) in EBITDA losses, and had net loss of ($855M).
Revenue (LTM)
Vaxcyte P&L
In the most recent fiscal year, Vaxcyte reported revenue of — and EBITDA of ($899M).
Vaxcyte expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($977M) | XXX | ($899M) | XXX | XXX | XXX |
| Net Profit | ($855M) | XXX | ($767M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vaxcyte Stock Performance
Vaxcyte has current market cap of $9B, and enterprise value of $8B.
Market Cap Evolution
Vaxcyte's stock price is $62.35.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $9B | 0.2% | XXX | XXX | XXX | $-5.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVaxcyte Valuation Multiples
Vaxcyte trades at (7.7x) EV/EBITDA.
EV / Revenue (LTM)
Vaxcyte Financial Valuation Multiples
As of April 18, 2026, Vaxcyte has market cap of $9B and EV of $8B.
Equity research analysts estimate Vaxcyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vaxcyte has a P/E ratio of (10.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/EBITDA | (7.7x) | XXX | (8.4x) | XXX | XXX | XXX |
| EV/EBIT | (7.5x) | XXX | (8.2x) | XXX | XXX | XXX |
| P/E | (10.5x) | XXX | (11.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (10.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vaxcyte Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vaxcyte Margins & Growth Rates
Vaxcyte's revenue in the last fiscal year grew by —.
Vaxcyte's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.
Vaxcyte Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 10% | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vaxcyte Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vaxcyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Huadong Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Haisco Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Krka | XXX | XXX | XXX | XXX | XXX | XXX |
| Eisai Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurobindo Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vaxcyte M&A Activity
Vaxcyte acquired XXX companies to date.
Last acquisition by Vaxcyte was on XXXXXXXX, XXXXX. Vaxcyte acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vaxcyte
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVaxcyte Investment Activity
Vaxcyte invested in XXX companies to date.
Vaxcyte made its latest investment on XXXXXXXX, XXXXX. Vaxcyte invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vaxcyte
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vaxcyte
| When was Vaxcyte founded? | Vaxcyte was founded in 2013. |
| Where is Vaxcyte headquartered? | Vaxcyte is headquartered in United States. |
| How many employees does Vaxcyte have? | As of today, Vaxcyte has over 507 employees. |
| Who is the CEO of Vaxcyte? | Vaxcyte's CEO is Grant E. Pickering. |
| Is Vaxcyte publicly listed? | Yes, Vaxcyte is a public company listed on Nasdaq. |
| What is the stock symbol of Vaxcyte? | Vaxcyte trades under PCVX ticker. |
| When did Vaxcyte go public? | Vaxcyte went public in 2020. |
| Who are competitors of Vaxcyte? | Vaxcyte main competitors are Huadong Medicine, Haisco Pharmaceutical, Krka, Eisai Co.. |
| What is the current market cap of Vaxcyte? | Vaxcyte's current market cap is $9B. |
| Is Vaxcyte profitable? | No, Vaxcyte is not profitable. |
| What is the current EBITDA of Vaxcyte? | Vaxcyte has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Vaxcyte? | Current EBITDA multiple of Vaxcyte is (7.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.